The Drug Screening Market was valued at USD 9.45 billion in 2024, and is projected to reach USD 11.99 billion by 2030, rising at a CAGR of 4.10%. The market is driven by increasing workplace safety concerns, regulatory compliance, and the requirement for accurate detection of substance abuse, aided by technological advancements in testing methods.
The increase in number of adults in contact with drug and alcohol services in England has increased from 275,896 in 2020-2021¬ to 289,215 in 2021-2022, representing a 4.8% rise, which signifies a growing prevalence of substance abuse in the country. The rising prevalence of substance abuse further propels the need for effective prevention and treatment strategies, including the expansion of access to evidence-based treatment options and public health campaigns to raise awareness about the risks of drug and alcohol misuse.
Furthermore, the incidence of illegal substance uses amongst Americans aged 12 and older in 2020 was around 37.31 million, and shows a 3.8% year-over-year increase over the years; this rising prevalence serves as a significant driver for the market. This increase highlights the urgent need for comprehensive drug screening programs in workplaces, schools, and healthcare settings to ensure safety, compliance with regulations, and provision of appropriate care and support for individuals struggling with substance abuse.
Furthermore, initiatives by market players such as new product launches, mergers, acquisitions, and others contribute to market growth. For instance, in February 2024, Mobile Health, the leading drug testing provider in NYC, launched rapid drug testing for employers, ensuring results in an hour or less. With a focus on urine-based testing for accuracy and versatility, this innovation advances the hiring procedure, revolutionizing talent acquisition in NYC. In addition, in December 2023, the FDA's approval of the AvertD test, which assesses an individual's risk of developing opioid use disorder through genetic markers, marks a significant innovation in the fight against the opioid crisis. This test, developed by AutoGenomics, Inc., is designed to be used before a patient is first exposed to oral opioid pain medications, particularly in patients scheduled for surgical procedures. The test is intended to help patients and healthcare providers make informed decisions about opioid use, potentially reducing the risk of addiction and misuse.
This product will be delivered within 2 business days.
The increase in number of adults in contact with drug and alcohol services in England has increased from 275,896 in 2020-2021¬ to 289,215 in 2021-2022, representing a 4.8% rise, which signifies a growing prevalence of substance abuse in the country. The rising prevalence of substance abuse further propels the need for effective prevention and treatment strategies, including the expansion of access to evidence-based treatment options and public health campaigns to raise awareness about the risks of drug and alcohol misuse.
Furthermore, the incidence of illegal substance uses amongst Americans aged 12 and older in 2020 was around 37.31 million, and shows a 3.8% year-over-year increase over the years; this rising prevalence serves as a significant driver for the market. This increase highlights the urgent need for comprehensive drug screening programs in workplaces, schools, and healthcare settings to ensure safety, compliance with regulations, and provision of appropriate care and support for individuals struggling with substance abuse.
Furthermore, initiatives by market players such as new product launches, mergers, acquisitions, and others contribute to market growth. For instance, in February 2024, Mobile Health, the leading drug testing provider in NYC, launched rapid drug testing for employers, ensuring results in an hour or less. With a focus on urine-based testing for accuracy and versatility, this innovation advances the hiring procedure, revolutionizing talent acquisition in NYC. In addition, in December 2023, the FDA's approval of the AvertD test, which assesses an individual's risk of developing opioid use disorder through genetic markers, marks a significant innovation in the fight against the opioid crisis. This test, developed by AutoGenomics, Inc., is designed to be used before a patient is first exposed to oral opioid pain medications, particularly in patients scheduled for surgical procedures. The test is intended to help patients and healthcare providers make informed decisions about opioid use, potentially reducing the risk of addiction and misuse.
Drug Screening Market Report Highlights
- Consumables held the largest revenue share of 34.5% in 2024, attributed to their essential role in rapid, accurate, and on-site testing. Furthermore, frequent product launches and the need for efficient substance detection across workplaces and healthcare settings also fuel this segment’s growth
- Services and others are expected to grow at a CAGR of 4.1% over the forecast period, owing to the increasing need for specialized drug screening services, including laboratory analysis and support for compliance with regulatory standards.
- Urine samples dominated the market with the largest revenue share of 41.3% in 2024, primarily driven by their noninvasive, simple, and convenient collection process, which makes them suitable for both workplace and clinical settings.
- Oral fluid samples are expected to grow at a significant CAGR over the forecast period, driven by their ease of collection, minimal privacy concerns, and lower risk of sample adulteration.
- In 2024, drug treatment led the market and accounted for the largest revenue share. Hospitals are expected to grow at the fastest CAGR of 5.2% from 2025 to 2030.
- North America dominated the global drug screening market with the largest revenue share in 2024, driven by rising substance abuse rates, stringent workplace safety regulations, and increasing government initiatives aimed at controlling drug-related issues.
This report addresses:
- Market intelligence to enable effective decision-making
- Market estimates and forecasts from 2018 to 2030
- Growth opportunities and trend analyses
- Segment and regional revenue forecasts for market assessment
- Competition strategy and market share analysis
- Product innovation listings for you to stay ahead of the curve
Why Should You Buy This Report?
- Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
- Competitive Landscape: Explore the market presence of key players.
- Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
- Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.
This product will be delivered within 2 business days.
Table of Contents
Chapter 1. Methodology and Scope
Chapter 2. Executive Summary
Chapter 3. Global Drug Screening Market Variables, Trends, & Scope
Chapter 4. Global Drug Screening Market: Product Type Business Analysis
Chapter 5. Global Drug Screening Market: Sample Type Business Analysis
Chapter 6. Global Drug Screening Market: End Use Business Analysis
Chapter 7. Global Drug Screening Market: Regional Estimates & Trend Analysis
Chapter 8. Competitive Landscape
List of Tables
List of Figures
Companies Mentioned
The major companies featured in this Drug Screening market report include:- Abbott
- Quest Diagnostics Incorporated
- F. Hoffmann-La Roche Ltd
- Thermo Fisher Scientific Inc.
- Siemens Healthcare AG
- Laboratory Corporation of America Holdings
- Alfa Scientific Designs, Inc.
- OraSure Technologies, Inc.
- Omega Laboratories, Inc.
- Drägerwerk AG & Co. KGaA
- Bio-Rad Laboratories, Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 110 |
| Published | May 2025 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 9.45 Billion |
| Forecasted Market Value ( USD | $ 11.99 Billion |
| Compound Annual Growth Rate | 4.1% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
